日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Specific inhibition of bile acid transport alters plasma lipids and GLP-1

特异性抑制胆汁酸转运会改变血浆脂质和 GLP-1 水平。

Rudling, Mats; Camilleri, Michael; Graffner, Hans; Holst, Jens Juul; Rikner, Leif

Corrigendum: Prescription of and Adherence to Non-Steroidal Anti-Inflammatory Drugs and Gastroprotective Agents in At-Risk Gastrointestinal Patients

更正:高危胃肠道患者的非甾体类抗炎药和胃保护剂的处方及依从性

Shaheen, Nicholas J; Falk, Gary W; Iyer, Prasad G; Gerson, Lauren B; Chey, William D; Camilleri, Michael; Chang, Lin; Rikner, Leif; Graffner, Hans; Theocharidou, Eleni; Pieri, Giulia; Mohammad, Ali Omar; Cheung, Michelle; Cholongitas, Evangelos; Banwari, Agarwal; Burroughs, Andrew K; Lanas, Angel; Polo-Tomás, Mónica; Roncales, Pilar; Gonzalez, Miguel A; Zapardiel, Javier

A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation

一项针对慢性特发性便秘的随机安慰剂对照 IIb 期试验,研究了胆汁酸转运体抑制剂 a3309 的疗效。

Chey, William D; Camilleri, Michael; Chang, Lin; Rikner, Leif; Graffner, Hans

Interferon beta-1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding study

干扰素β-1a用于维持克罗恩病患者缓解期:一项II期剂量探索研究的结果

Pena Rossi, Claudia; Hanauer, Stephen B; Tomasevic, Ratko; Hunter, John O; Shafran, Ira; Graffner, Hans